Table 3 The effect of methotrexate on lipid profiles and cardiovascular risk parameters in psoriatic patients with and without arthritis

ApoA1, g/L

1.08 (0.18)

1.07 (0.17)

.1026

1.07 (0.18)

1.03 (0.15)

.0001

ApoB, g/L

0.76 (0.15)

0.72 (0.15)

.0003

0.70 (0.17)

0.64 (0.16)

<.0001

TC, mmol/L

4.95 (0.89)

4.75 (0.89)

.0007

4.61 (0.89)

4.39 (0.90)

<.0001

TG, mmol/L

1.74 (1.13)

1.61 (0.96)

.0410

1.57 (1.02)

1.63 (1.86)

.6930

HDL-C, mmol/L

1.23 (0.32)

1.20 (0.30)

.0370

1.21 (0.29)

1.17 (0.27)

.0110

LDL, mmol/L

3.06 (0.77)

2.96 (0.76)

.0632

2.84 (0.81)

2.68 (0.81)

.0001

LPA, mg/L

147.9 (158.0)

137.1 (149.5)

.0055

139.6 (175.2)

127.7 (173.9)

<.0001

ApoB:ApoA1 ratio

0.72 (0.19)

0.69 (0.17)

.0076

0.67 (0.19)

0.64 (0.18)

.0011

TC:HDL ratio

4.21 (1.07)

4.13 (0.98)

.1303

3.98 (1.03)

3.90 (0.18)

.1121

LDL:HDL ratio

2.62 (0.82)

2.59 (0.79)

.5030

2.47 (0.85)

2.40 (0.86)

.0551

LDL:ApoB ratio

4.03 (0.59)

4.11 (0.58)

.0250

4.08 (0.56)

4.14 (0.59)

.0464